LPL Financial LLC cut its position in shares of Boston Scientific Co. (NYSE:BSX) by 27.9% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 94,959 shares of the medical equipment provider’s stock after selling 36,690 shares during the quarter. LPL Financial LLC’s holdings in Boston Scientific were worth $2,594,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in BSX. BlackRock Inc. boosted its position in shares of Boston Scientific by 8.7% during the first quarter. BlackRock Inc. now owns 106,292,471 shares of the medical equipment provider’s stock valued at $2,903,912,000 after purchasing an additional 8,510,783 shares in the last quarter. Two Sigma Advisers LP boosted its position in shares of Boston Scientific by 59.0% during the fourth quarter. Two Sigma Advisers LP now owns 7,426,814 shares of the medical equipment provider’s stock valued at $184,111,000 after purchasing an additional 2,756,504 shares in the last quarter. Eaton Vance Management boosted its position in shares of Boston Scientific by 42.3% during the first quarter. Eaton Vance Management now owns 6,564,617 shares of the medical equipment provider’s stock valued at $179,345,000 after purchasing an additional 1,951,777 shares in the last quarter. Two Sigma Investments LP boosted its position in shares of Boston Scientific by 79.2% during the fourth quarter. Two Sigma Investments LP now owns 3,702,539 shares of the medical equipment provider’s stock valued at $91,786,000 after purchasing an additional 1,635,881 shares in the last quarter. Finally, Cannell Peter B & Co. Inc. bought a new stake in shares of Boston Scientific during the first quarter valued at approximately $33,890,000. Institutional investors own 89.12% of the company’s stock.

In other news, SVP Jeffrey B. Mirviss sold 19,323 shares of the business’s stock in a transaction on Thursday, June 14th. The stock was sold at an average price of $32.64, for a total value of $630,702.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP David A. Pierce sold 1,650 shares of the business’s stock in a transaction on Thursday, June 7th. The stock was sold at an average price of $30.83, for a total value of $50,869.50. The disclosure for this sale can be found here. Insiders sold 163,030 shares of company stock valued at $5,211,897 in the last 90 days. Company insiders own 0.73% of the company’s stock.

Shares of Boston Scientific opened at $32.70 on Friday, Marketbeat.com reports. The firm has a market cap of $45.12 billion, a price-to-earnings ratio of 25.15, a P/E/G ratio of 2.33 and a beta of 0.77. Boston Scientific Co. has a 12-month low of $24.54 and a 12-month high of $37.30. The company has a debt-to-equity ratio of 0.68, a current ratio of 0.82 and a quick ratio of 0.59.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 25th. The medical equipment provider reported $0.33 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.32 by $0.01. The business had revenue of $2.38 billion during the quarter, compared to analysts’ expectations of $2.34 billion. Boston Scientific had a return on equity of 25.10% and a net margin of 1.21%. The firm’s quarterly revenue was up 10.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.29 earnings per share. research analysts anticipate that Boston Scientific Co. will post 1.39 EPS for the current year.

Several research firms recently weighed in on BSX. Sanford C. Bernstein began coverage on Boston Scientific in a research report on Wednesday. They set an “outperform” rating and a $38.00 price target on the stock. ValuEngine upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research report on Monday, June 11th. Argus lifted their price target on Boston Scientific from $32.00 to $36.00 and gave the company a “buy” rating in a research report on Thursday, June 7th. Zacks Investment Research upgraded Boston Scientific from a “hold” rating to a “buy” rating and set a $34.00 price target on the stock in a research report on Friday, May 11th. Finally, Canaccord Genuity restated a “buy” rating and set a $36.00 price target on shares of Boston Scientific in a research report on Wednesday, April 25th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eighteen have issued a buy rating and three have assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $32.70.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.